Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.49 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.49 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.46 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.46 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12814503 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 | |
| SCHEMBL3720824 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL30891041 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 | |
| SCHEMBL3567491 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 | |
| SCHEMBL3563953 | 0.80 | RAB9A (0.52) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 | |
| SCHEMBL30891215 | 0.80 | RAB9A (0.52) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 | |
| SCHEMBL1770090 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 | |
| SCHEMBL11263318 | 0.78 | ALDH1A1 (0.44) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 | |
| SCHEMBL7307217 | 0.78 | ALDH1A1 (0.47) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 | |
| SCHEMBL1207982 | 0.78 | ALDH1A1 (0.57) | SMN1; SMN2HTTALDH1A1TXNRD1TXNRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2025-09-11 | — | — | US | disclosed |
| CN-113292539-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-116410146-A | One-step process for converting polyols to nitrogen-containing heterocycles using heterogeneous metal catalysts | 浙江大学 | 2023-07-11 | — | — | CN | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| CN-113087674-B | Method for synthesizing quinoxaline compound under catalysis of visible light induced photosensitizer | 河南大学 | 2022-06-17 | — | — | CN | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| CN-113292539-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-108026072-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-113087674-A | Method for synthesizing quinoxaline compound under visible light induced iron catalysis condition | 河南大学 | 2021-07-09 | — | — | CN | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| US-5204347-A | Reduction in intraocular pressure; increase renal flow; alteration in the rate of fluid transport in the gastrointestinal tract | ALLERGAN, INC. (US) | 1993-04-20 | — | — | US | disclosed |
| WO-1992013855-A1 | (2-IMIDAZOLIN-2-YLAMINO) TETRAHYDROQUINOLAXINES AND METHODS FOR USING SAME | ALLERGAN, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| US-5089025-A | HAIR DYE COMPOSITIONS AND CERTAIN 1,2,3,4-TETRAHYDRONITROQUINOXALINES USEFUL THEREIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1992-02-18 | — | — | US | disclosed |
| US-5077292-A | Gastrointestinal disordes; kidney and vision defects | ALLERGAN, INC. (US) | 1991-12-31 | — | — | US | disclosed |
| US-5021416-A | Glaucoma | ALLERGAN, INC. (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0426719-A1 | A HAIR DYE | Henkel Kommanditgesellschaft auf Aktien (DE) | 1991-05-15 | — | — | EP | disclosed |
| EP-0426390-A2 | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure | ALLERGAN, INC. (US) | 1991-05-08 | — | — | EP | disclosed |
| EP-0422878-A1 | (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same | ALLERGAN, INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| WO-1990001050-A1 | A HAIR DYE | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-02-08 | — | — | WO | disclosed |
| EP-0353531-A1 | Hair dye | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180471-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | SMN1; SMN2 2641/4885HTT 1354/4885ALDH1A1 2345/4885 |
| US-20250282748-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | SMN1; SMN2 2641/4885HTT 1354/4885ALDH1A1 2345/4885 |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | SMN1; SMN2 2641/4885HTT 1354/4885ALDH1A1 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.